Clinical trials: Lipemia
Hypercholesterolemia
DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia
This clinical trial is being performed to investigate the effect of 12 weeks treatment with rosuvastatin and atorvastatin in bringing subjects to their established EAS LDL-C target goal.
- Trial name
- NCT00241488
- Testing
- Rosuvastatin
- Where
- 34 sites in China, Hong Kong and 4 more
- Volunteers
- 1,362 people
- Sponsor
- AstraZeneca
Familial Chylomicronemia Syndrome (FCS)
CS-121 APOC3 Base Editing in FCS
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid…
- Trial name
- NCT07176923
- Testing
- CS-121
- Where
- China
- Volunteers
- 15 people
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
Hypercholesterolemia, Hyperlipidemias
Lipid-lowering Effect of Plant Stanol Yogurt
To determine the effect of investigational products on serum LDL cholesterol.
- Conditions
- Hypercholesterolemia, Hyperlipidemias, Dyslipidemias
- Trial name
- NCT01882517
- Testing
- Yogurt that contains plant stanol esters
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Raisio Group
Hyperlipidemia
Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
The objective of this study is to evaluate the efficacy and safety of ARI-3037MO compared to placebo in reducing low-density lipoprotein cholesterol (LDL-C) levels in subjects with dyslipidemia.
- Trial name
- REASCEND (NCT02532218)
- Testing
- ARI-3037MO
- Where
- 19 sites in United States
- Volunteers
- 176 people
- Sponsor
- Arisaph Pharmaceuticals Inc
Hyperlipidemia
Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects
The purpose of this study is to investigate the safety tolerability, and PK profile of K-312 and its metabolites in healthy Japanese and non-Japanese adults.
- Trial name
- NCT02676596
- Testing
- K-312 10 mg QD, K-312 25 mg QD, K-312 50 mg QD
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Hypertriglyceridemia
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of TG in adults with elevated TG and RC.
- Trial name
- TYDAL-TIMI 78 (NCT07028749)
- Testing
- MAR001
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 316 people
- Sponsor
- Marea Therapeutics
Hypercholesterolemia
Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects
Primary Objective: To assess the pharmacodynamic profile of alirocumab (SAR236553/REGN727) administered either alone or on top of ezetimibe or fenofibrate, based on low-density lipoprotein -cholesterol (LDL-C).
- Trial name
- NCT01723735
- Testing
- Alirocumab, Ezetimibe, Fenofibrate
- Where
- 2 sites in France
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hyperlipidemias
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a fixed-dose combination (FDC) is effective and safe versus its individual components and placebo in patients with elevated LDL cholesterol…
- Trial name
- NCT03337308
- Testing
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe
- Where
- 5 sites in United States
- Volunteers
- 382 people
- Sponsor
- Esperion Therapeutics, Inc.
Hypercholesterolemia, Hypertension
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.
- Trial name
- NCT02178098
- Testing
- ETC-1002
- Where
- 43 sites in United States
- Volunteers
- 143 people
- Sponsor
- Esperion Therapeutics, Inc.
Hypercholesterolemia
The Effect of Shuhua Milk Fortified With Plant Sterol Esters on Serum Cholesterol in Human
The purpose of this study is to determine whether YiLi Xinhuo Shuhua Milk is effective in reducing the serum cholesterol in human with hypercholesterolemia.
- Trial name
- NCT02475018
- Testing
- Milk fortified with plant sterol esters, Plain milk
- Where
- China
- Volunteers
- 179 people
- Sponsor
- Inner Mongolia Yili Industrial Group Co., Ltd
Hypercholesterolemia
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)
To Evaluate and Compare the Efficacy and Safety of Ezetimibe Plus Atorvastatin Versus Atorvastatin in Hypercholesterolemic Patients at High Risk for Coronary Heart Disease Not Adequately Controlled on Atorvastatin 40 mg.
- Trial name
- NCT00276484
- Testing
- atorvastatin, ezetimibe
- Volunteers
- 579 people
- Sponsor
- Organon and Co
Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS
This is a treatment program for the use of plozasiran in adults (AROAPOC3-EAP-002) and adolescents (AROAPOC3-EAP-003) with familial chylomicronemia syndrome (FCS) as well as in adults (AROAPOC3-EAP-004) with high risk severe…
- Trial name
- NCT06796426
- Testing
- Plozasiran
- Where
- United States
- Sponsor
- Arrowhead Pharmaceuticals
Hypercholesterolaemia
Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets
Single dose oral bioequivalence study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated tablets in healthy adult human subjects under fasting conditions.
- Trial name
- NCT07170852
- Testing
- Bempedoic acid film coated tablet, Nilemdo® Film-coated tablets
- Where
- India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Hypertriglyceridemia
Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia
The purpose of this study is to determine the safety and efficacy of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia…
- Trial name
- NCT01350999
- Testing
- omega-3-acid ethyl esters 90 (TAK-085), Eicosapentaenoic acid-ethyl (EPA)
- Volunteers
- 503 people
- Sponsor
- Takeda
Hypercholesterolemia
Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease
To determine in hypercholesterolemic subjects with chronic, well-compensated liver disease, the percent change from baseline to Week 12 in serum LDL-C of pravastatin 80 mg compared to placebo.
- Trial name
- NCT00529178
- Testing
- Pravastatin
- Volunteers
- 232 people
- Sponsor
- Bristol-Myers Squibb
Erectile Dysfunction
Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia
This study is being conducted in US to obtain information on the efficacy, safety, and duration of erection of flexible-dose regime of vardenafil compared to placebo (dummy medication with no pharmacological activity), in…
- Trial name
- NCT00663845
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Volunteers
- 395 people
- Sponsor
- Bayer
Hypercholesterolemia, Coronary Disease
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)
The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
- Trial name
- NCT00092612
- Testing
- MK0653, ezetimibe
- Volunteers
- 372 people
- Sponsor
- Organon and Co
Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol
Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction
The study is to assess the long-term safety, tolerability, and efficacy after 48 and 72 weeks with monthly (Q4W [<31 days]) dosing of subcutaneous (SC) LIB003 300 mg administered in patients with CVD or at high risk for CVD…
- Conditions
- Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia
- Trial name
- LIBerate-OLE (NCT04798430)
- Testing
- lerodalcibep
- Where
- 12 sites in United States, India and 4 more
- Volunteers
- 2,000 people
- Sponsor
- LIB Therapeutics LLC
Dyslipidemia, Hypercholesterolemia
A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)
This study is being done to provide valid data on the evolution of a cohort of French participants treated with ezetimibe, alone or in combination with a statin, to be used in simulation models for cardiovascular disease (CVD).
- Trial name
- MOBS (NCT01414192)
- Volunteers
- 3,215 people
- Sponsor
- Organon and Co
Hypercholesterolemia
MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)
A study to determine lipid changing effects of MK0524A when compared to niacin extended release (NIASPAN) and placebo.
- Trial name
- NCT00533312
- Testing
- MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks, Comparator : niacin / Duraton of Treatment: 4 Weeks
- Volunteers
- 407 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.